GO
Loading...

Life Sciences

More

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been dispatched to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The World Health Organization said on Thursday the Ebola outbreak in West Africa, the worst in history, appears to be waning but cautioned against complacency.

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been shipped to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The vaccine, co-developed by the National Institutes of Health in the United States and Okairos, a biotechnology firm acquired by GSK in 2013, is currently being tested...

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • The cost of halting a pandemic? $344 billion: Study Saturday, 17 Jan 2015 | 12:15 PM ET
    A custodial worker wears a mask and eye protection to guard against the Ebola virus as he prepares to clean Ruth Cherry Intermediate School in Dallas.

    How much would it cost world governments to insulate their economies from global pandemics. Would you believe nearly $344 billion?

  • LONDON, Jan 16- Johnson& Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros from Europe's Innovative Medicines Initiative to speed development. The new initiative will see J&J join with institutions including the London School of Hygiene& Tropical Medicine, the University of...

  • SHANGHAI, Jan 15- China has approved a new polio vaccine, the first of its kind to be produced in the country, a month after local authorities gave the green light for a home-grown Ebola vaccine amid Beijing's push to become a world leader in producing innovative drugs. "This new vaccine is a critically important weapon in the fight against polio as the world nears...

  • Jan 11- Canada's Tekmira Pharmaceuticals Corp agreed to buy Pennsylvania- based OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods. The implied market value of the merged company is about $750 million, based on Tekmira stock's closing price of $15.70 on the Nasdaq on Jan. 9, the companies said in a...

  • *Initial Phase I clinical study starts in Britain. *First tests in Britain, more planned in U.S. and Africa. LONDON, Jan 6- Johnson& Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

  • *Initial Phase I clinical study starts at Oxford University. *Further tests planned for United States and Africa. LONDON, Jan 6- Johnson& Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

  • Dec 23- The U.S. Department of Health and Human Services awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine...

  • Dec 19- Shares of cancer drug developer Juno Therapeutics Inc soared as much as 65 percent in their market debut on Friday, capping a big year for biotech IPOs. Shares were priced at $24 per share, above the expected $21- $23. As of Sept. 30, Seattle- based Juno had raised about $314 million in private venture funding from investors including Amazon.com Inc co-founder...

  • Dec 19- Shares of Juno Therapeutics Inc, a biopharmaceutical company working on cancer treatments, rose as much as 64.5 percent in their market debut, valuing the company at about $3 billion. The stock touched a high of $39.50 shortly after trading started on the Nasdaq on Friday. The offering was priced at $24 per share, above the raised range of $21- $23.

  • GENEVA, Dec 19- Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information. Countries where the trials are planned-- Cameroon, Ghana, Mali, Nigeria and Senegal-- should receive and review the additional...

  • *Shares in GSK partner Agenus jump 10 percent. LONDON, Dec 18- An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. The data suggests the British company's new shot could be a strong competitor for Merck& Co's established vaccine...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • LONDON/ GENEVA, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines, as one experimental shot hit a snag in a Swiss clinical trial after some subjects reported joint pains. GAVI, which is funded by governments and the Bill& Melinda Gates Foundation, said it was ready to begin procurement as soon as the...

  • LONDON, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines and was ready to begin procurement as soon as the World Health Organization recommends one for use. Clinical trials with experimental shots are now underway as experts race to contain an epidemic that has killed more than 6,000 people in...

  • LONDON, Dec 11- GAVI, the global vaccines alliance, has committed up to $300 million to buy Ebola vaccines and is ready to begin procurement as soon as the World Health Organisation recommends one for use, the alliance said on Thursday. Up to an additional $90 million could also be used to support countries to introduce the vaccines and to rebuild their health...

  • Arca's potential Ebola drug gets "orphan drug status" Wednesday, 10 Dec 2014 | 11:19 AM ET

    Dec 10- Arca Biopharma Inc said the U.S. Food and Drug Administration granted its experimental drug orphan drug status as a potential treatment for viral hemorrhagic fever after exposure to the Ebola virus. The Westminster, Colorado- based company, whose stock rose about 11 percent on Wednesday, joins a list of drugmakers looking for ways to fight the largest...

  • This data represents a "quantum leap" in the management of this disorder by shifting from "life-long symptom management to once-and-done cures," Roth Capital Partner's Debjit Chattopadhyay said, raising his price target on the stock to $90 from $50. LentiGlobin's results read-through favorably to the sickle-cell indication, Piper Jaffray analysts said,...